Sunitinib

COMPOSITION:

Each capsule contains Sunitinib malate 16.71 mg equivalent to Sunitinib………………………12.5mg.

Each capsule contains Sunitinib malate 16.71 mg equivalent to Sunitinib………………………25mg.

Each capsule contains Sunitinib malate 16.71 mg equivalent to Sunitinib………………………50mg.

INDICATION:

LuciSuni is a kinase inhibitor indicated for the treatment of:

• Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate.

• Advanced renal cell carcinoma (RCC).

• Progressive, well-differentiated pancreatic neuroendocrine tumors (pNET) in patients with

unresectable locally advanced or metastatic disease.

DOSAGE AND USE

GIST and RCC:

• 50 mg orally once daily, with or without food, 4 weeks on treatment followed by 2 weeks off.

pNET:

• 37.5 mg orally once daily, with or without food, continuously without a scheduled off treatment period.

Dose Modification:

• Dose interruptions and/or dose adjustments of 12.5 mg recommended based on individual

safety and tolerability.

STORAGE:

In a dry place and store at 20°C to 25°C.

MANUFACTURED AND MARKETED BY

LUCIUS PHARMACEUTICALS(LAO) CO., LTD

No.26, Thongmang village, Xaythany district, Vientiane Capital, Laos

WARNING:

Keep medicine out of reach of Children. Do not administer LuciSuni during Pregnancy and Lactation.